Roy B J, Cornish J D, Clark R H
Department of Pediatrics, University of South Alabama School of Medicine, Mobile, USA.
Pediatrics. 1995 Apr;95(4):573-8.
We evaluated the effect of venovenous extracorporeal membrane oxygenation (ECMO) on renal function and fluid balance in neonates with severe respiratory failure.
We retrospectively reviewed the charts of 30 consecutive patients who met criteria for treatment with ECMO. Twelve were managed without ECMO (comparison group) and 18 were treated with venovenous ECMO (treatment group).
The study was conducted in a single level III neonatal intensive care unit in a regional children's hospital accepting medical and surgical neonatal transfers. Our hospital does not have an inborn service.
Neonates were included if their gestational age was more than 34 weeks, they weighed more than 2 kg, and their respiratory failure was severe enough to warrant consideration of ECMO as a mode of support. All the neonates in this study were treated with high-frequency ventilation before being considered for ECMO; none were treated with nitric oxide. Criteria used to determine whether a neonate was a candidate for ECMO included: (1) alveolar-arterial oxygen difference greater than 60 kPa (610 torr) for 8 hours; (2) alveolar-arterial oxygen difference greater than 59 kPa (605 torr) and a peak airway pressure greater than 3.7 kPa (38 cm H2O) for 4 hours; (3) oxygenation index greater than 40 on three of five postductal blood gases obtained at least 30 minutes apart and unstable patient condition; or (4) refractory, severe respiratory failure with sudden decompensation (partial pressure of arterial oxygen 3.4 kPa or lower, 35 torr) despite maximal medical management for 2 hours. We did not include patients with congenital diaphragmatic hernia.
There were no differences between the groups in gestational age, birth weight, age at admission, gender, or diagnoses. Over the course of the 108 hours reviewed for each case, neonates treated with ECMO had higher positive fluid balance (P < .001), lower urine flow rates (P < .01), and higher blood urea nitrogen (P < .01) and creatinine (P < .01) levels than neonates managed without ECMO. There were no differences in mean blood pressure, protein intake, serum albumin, or use of diuretic therapy that might explain the differences between the groups.
We conclude that venovenous ECMO is associated with transient impairment in renal function and marked fluid retention.
我们评估了静脉-静脉体外膜肺氧合(ECMO)对重症呼吸衰竭新生儿肾功能和液体平衡的影响。
我们回顾性分析了连续30例符合ECMO治疗标准患者的病历。其中12例未接受ECMO治疗(对照组),18例接受静脉-静脉ECMO治疗(治疗组)。
本研究在一家接收新生儿内科和外科转诊的地区儿童医院的三级新生儿重症监护病房进行。我院没有新生儿出生服务。
纳入的新生儿胎龄大于34周,体重超过2 kg,且呼吸衰竭严重到足以考虑将ECMO作为一种支持方式。本研究中的所有新生儿在考虑使用ECMO之前均接受高频通气治疗;均未接受一氧化氮治疗。用于确定新生儿是否为ECMO候选者的标准包括:(1)肺泡-动脉氧分压差大于60 kPa(610托)持续8小时;(2)肺泡-动脉氧分压差大于59 kPa(605托)且气道峰压大于3.7 kPa(38 cm H₂O)持续4小时;(3)在至少间隔30分钟采集的五次导管后血气中的三次中氧合指数大于40且患者病情不稳定;或(4)尽管进行了2小时的最大程度药物治疗仍出现难治性严重呼吸衰竭且突然失代偿(动脉血氧分压3.4 kPa或更低,35托)。我们未纳入先天性膈疝患者。
两组在胎龄、出生体重、入院年龄、性别或诊断方面无差异。在对每个病例回顾的108小时过程中,接受ECMO治疗的新生儿比未接受ECMO治疗的新生儿有更高的液体正平衡(P < .001)、更低的尿流率(P < .01)以及更高的血尿素氮(P < .01)和肌酐(P < .01)水平。两组在平均血压、蛋白质摄入量、血清白蛋白或利尿剂治疗的使用方面无差异,这些因素可能解释两组之间的差异。
我们得出结论,静脉-静脉ECMO与肾功能的短暂损害和明显的液体潴留有关。